Anti-angiogenic active immunotherapy: A new approach to cancer treatment

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1105-1114

  Pan, Jianping ^a   Jin, Pengfeng ^a   Yan, Jie ^a   Kabelitz, Dieter ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Active immunotherapy; Angiogenesis; Tumor

Indexed keywords

ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTEGRIN; LEGUMAIN; MATRIX METALLOPROTEINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACTIVE IMMUNIZATION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL THERAPY; HUMAN; MOLECULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANIMALS; CANCER VACCINES; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44249087196     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0452-2     Document Type: Review

References (56)

1. Albini A, Melchiori A, Santi L et al (1991) Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775-779
2. Asakage M, Tsuno NH, Kitayama J et al (2006) Early-outgrowth of endothelial progenitor cells can function as antigen-presenting cells. Cancer Immunol Immunother 55:708-716
3. Bequet-Romero M, Ayala M, Acevedo BE, Rodríguez EG, Ocejo OL, Torrens I, Gavilondo JV (2007) Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 10:23-34
4. Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5:13-17
5. Dias S, Hattori K, Zhu Z et al (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511-521
6. Caldini R, Barletta E, Del Rosso M et al (2005) FGF2-mediated upregulation of urokinase-type plasminogen activator expression requires a MAP-kinase dependent activation of poly (ADP-ribose) polymerase. J Cell Physiol 202:125-134
7. + T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J Immunother 29:32-40
8. Ferrajoli A, Manshouri T, Estrov Z et al (2001) High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7:795-799
9. Ferrara N (2002) VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2:795-803
10. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 6:669-676
11. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
12. Gutheil JC, Campbell TN, Pierce PR et al (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the Integrin αvβ3. Clin Cancer Res 6:3056-3061
13. Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689-708
14. He QM, Wei YQ, Tian L et al (2003) Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278:21831-21836
15. Hofmeister V, Schrama D, Becker JC et al (2008) Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 57:1-17
16. Hu B, Wei YQ, Tian L et al (2005) Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. J Immunother 28:236-244
17. Itoh T, Tanioka M, Yoshida H et al (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048-1051
18. Kamstock D, Elmslie R, Thamm D, Dow S (2007) Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 56:1299-1309
19. Kanda S, Miyata Y, Kanetake H (2006) Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol 11:90-107
20. Karsan A, Yee E, Poirier GG et al (1997) Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol 151:1775-1784
21. Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505-515
22. Kerbel RS, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739
23. Kornberg TB, Krasnow MA (2000) The Drosophila genome sequence: implications for biology and medicine. Science 287:2218-2220
24. Lee SH, Mizutani N, Mizutani M et al (2006) Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 55:1565-1574
25. Lewen S, Zhou H, Hu HD et al (2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother (in press)
26. Li Y, Wang MN, Li H et al (2002) Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195:1575-1584
27. Liu JY, Wei YQ, Yang L et al (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102:1815-1823
28. Liu C, Sun C, Huang H et al (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63:2957-2964
29. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336
30. Luo Y, Zhou H, Krueger J et al (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116:2132-2141
31. Lou YY, Wei QY, Yang L et al (2002) Immunogene therapy of tumors with vaccine based on the ligand binding domain of chick homologous integrin beta3. Immunol Invest 31:51-69
32. Murthy RV, Arbman G, Gao J et al (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 11:2293-2299
33. Nair S, Boczkowski D, Moeller B et al (2003) Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102:964-971
34. Nithammer AG, Xiang R, Becker JC et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369-1375
35. Oosterling SJ, van der Bij GJ, Meijer GA et al (2005) Macrophages direct tumor histology and clinical outcome in a colon cancer model. J Pathol 207:147-155
36. Pan J, Heiser A, Marget M et al (2005) Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccine. Gene Ther 12:742-750
37. Pan J, Zhang M, Wang J et al (2004) Interferon-gamma is an autocrine mediator for dendritic cell maturation. Immunol Lett 94:141-151
38. Pan J, Zhang M, Wang J et al (2005) Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response. J Cancer Res Clin Oncol 131:468-478
39. Plum SM, Holaday JW, Ruiz A et al (2000) Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19:1294-1303
40. Plum SM, Vu HA, Mercer B et al (2004) Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Immunopharmacol Immunotoxicol 26:29-41
41. Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686
42. Reisfeld RA, Niethammer AG, Luo Y et al (2004) DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int Arch Allergy Immunol 133:295-304
43. Rini BI, Rathmell WK (2007) Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 13:741-746
44. Schneider BP, Sledge GW (2007) Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4:181-189
45. Shalaby F, Rossant J, Yamaguchi TP et al (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66
46. Shant K, Li CG (2001) Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 22:129-133
47. Shojaei F, Ferrara N (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87:227-230
48. St Croix B, Rago C, Velculescu V et al (2000) Genes expressed in human tumor endothelium. Science 289:1197-1202
49. Su JM, Wei YQ, Tian L et al (2003) Active immunotherapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 63:600-607
50. Tokuda H, Kozawa O, Uematsu T et al (2000) Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: divergent regulation by p44/p42 mitogen-activated protein kinase and p38 mitogen-activated protein kinase. J Bone Miner Res 15:2371-2379
51. Valesky M, Spang AJ, Fisher GW et al (2002) Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis. Mol Med 8:103-112
52. Veikkola T, Karkkainen M, Claesson-Welsh L et al (2000) Regulation of angiogenesis via endothelial growth factor receptors. Cancer Rev 60:203-212
53. Wada S, Tsunoda T, Baba T et al (2005) Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor 2. Cancer Res 65:4939-4946
54. Wei YQ, Huang MJ, Yang L et al (2001) Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factors as a model antigen. Pro Natl Acad Sci USA 98:11545-11550
55. Wei YQ, Wang QR, Zhao X et al (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6:1160-1166
56. William G, Stetler S (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103:1237-1241